The FDA has granted Fast Track designation to TEV-53408, an investigational anti-interleukin-15 antibody, for the treatment of celiac disease.

Janus kinase (JAK) inhibitors are not associated with an increased risk for gastrointestinal perforation (GIP) among patients with rheumatoid arthritis (RA), according to study results published in ...

Obesity is associated with a higher risk for remission failure among patients with early RA receiving MTX monotherapy, independent of comorbidities and lifestyle factors.

Intravenous ibuprofen appears safe and effective for older adults, reducing postoperative pain and opioid consumption.

Among older adults who sustained a hip fracture, a significant proportion demonstrated varying levels of resilience across different HRQOL domains.

Women residing in US neighborhoods with high social vulnerability have a higher risk for earlier natural menopause.

Both mild and moderate-to-severe psoriasis are significantly associated with an increased risk for sleep disorders.

The association of low-carbohydrate (LCD) and low-fat diets (LFD) with coronary heart disease (CHD) risk depends on the quality of macronutrients.

Physical activity levels have a significant association with a reduced incidence of restrictive spirometry patterns (RSP).

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.